Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anmol

Showing results (1431-1440 of 1,466) with videos related to

Pageof 147
Sort By:
Expert Review of Cardiovascular Therapy|October 9, 2018
Betrixaban for first-line venous thromboembolism prevention in acute medically ill patients with risk factors for venous thromboembolismTarek Nafee, C Michael Gibson, Megan K Yee, et al.
BMC Infectious Diseases|November 9, 2016
Understanding pneumococcal serotype 1 biology through population genomic analysisChrispin Chaguza, Jennifer E Cornick, Simon R Harris, et al.
Journal for Immunotherapy of Cancer|July 2, 2024
Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphomaSushma Bharadwaj, Eric Lau, Mark P Hamilton, et al.
Structure (London, England : 1993)|May 11, 2023
Molecular basis of SARS-CoV-2 Omicron variant evasion from shared neutralizing antibody responseAnamika Patel, Sanjeev Kumar, Lilin Lai, et al.
Biorxiv : the Preprint Server for Biology|November 3, 2022
Molecular basis of SARS-CoV-2 Omicron variant evasion from shared neutralizing antibody responseAnamika Patel, Sanjeev Kumar, Lilin Lai, et al.
BMJ Open Gastroenterology|December 18, 2024
Epidemiology of chronic and acute pancreatitis in India (EPICAP-India): protocol for a multicentre studyAnand Krishnan, Divya Pillai, Ritvik Amarchand, et al.
Journal of Medicinal Chemistry|October 20, 2023
Discovery of MK-1468: A Potent, Kinome-Selective, Brain-Penetrant Amidoisoquinoline LRRK2 Inhibitor for the Potential Treatment of Parkinson's DiseaseSolomon D Kattar, Anmol Gulati, Kaila A Margrey, et al.
Journal of Medicinal Chemistry|March 30, 2026
Discovery of Potent, Selective, CNS-Penetrant Macrocyclic LRRK2 Inhibitors for the Treatment of Parkinson's DiseaseElsie C Yu, Hua Zhou, Xin Yan, et al.
Blood Advances|March 14, 2025
Factors associated with survival following allogeneic transplantation for myeloid neoplasms harboring TP53 mutationsAnmol Baranwal, Kimberly Langer, Vedavyas Gannamani, et al.
RSC Medicinal Chemistry|August 6, 2021
Optimization of brain-penetrant picolinamide derived leucine-rich repeat kinase 2 (LRRK2) inhibitorsAnmol Gulati, Charles S Yeung, Blair Lapointe, et al.
Pageof 147

Showing results (1431-1440 of 1,466) with videos related to

Sort By:
Pageof 147
Expert Review of Cardiovascular Therapy|October 9, 2018
Betrixaban for first-line venous thromboembolism prevention in acute medically ill patients with risk factors for venous thromboembolismTarek Nafee, C Michael Gibson, Megan K Yee, et al.
BMC Infectious Diseases|November 9, 2016
Understanding pneumococcal serotype 1 biology through population genomic analysisChrispin Chaguza, Jennifer E Cornick, Simon R Harris, et al.
Journal for Immunotherapy of Cancer|July 2, 2024
Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphomaSushma Bharadwaj, Eric Lau, Mark P Hamilton, et al.
Structure (London, England : 1993)|May 11, 2023
Molecular basis of SARS-CoV-2 Omicron variant evasion from shared neutralizing antibody responseAnamika Patel, Sanjeev Kumar, Lilin Lai, et al.
Biorxiv : the Preprint Server for Biology|November 3, 2022
Molecular basis of SARS-CoV-2 Omicron variant evasion from shared neutralizing antibody responseAnamika Patel, Sanjeev Kumar, Lilin Lai, et al.
BMJ Open Gastroenterology|December 18, 2024
Epidemiology of chronic and acute pancreatitis in India (EPICAP-India): protocol for a multicentre studyAnand Krishnan, Divya Pillai, Ritvik Amarchand, et al.
Journal of Medicinal Chemistry|October 20, 2023
Discovery of MK-1468: A Potent, Kinome-Selective, Brain-Penetrant Amidoisoquinoline LRRK2 Inhibitor for the Potential Treatment of Parkinson's DiseaseSolomon D Kattar, Anmol Gulati, Kaila A Margrey, et al.
Journal of Medicinal Chemistry|March 30, 2026
Discovery of Potent, Selective, CNS-Penetrant Macrocyclic LRRK2 Inhibitors for the Treatment of Parkinson's DiseaseElsie C Yu, Hua Zhou, Xin Yan, et al.
Blood Advances|March 14, 2025
Factors associated with survival following allogeneic transplantation for myeloid neoplasms harboring TP53 mutationsAnmol Baranwal, Kimberly Langer, Vedavyas Gannamani, et al.
RSC Medicinal Chemistry|August 6, 2021
Optimization of brain-penetrant picolinamide derived leucine-rich repeat kinase 2 (LRRK2) inhibitorsAnmol Gulati, Charles S Yeung, Blair Lapointe, et al.
Pageof 147